PHARMABCINE INC.
10Patents
10Active
10Granted
46Portfolio score
Filing activity: Jun 26, 2007 → Dec 27, 2018 · 1 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10106622B2 | Human antibody specific to c-Met and preparation method thereof | Chemistry; Metallurgy | 6 | Active |
| US9963512B2 | Dual-target antibody targeting VEGFR-2 and DLL4, and pharmaceutical composition including same | Physics | 1 | Active |
| US9150650B2 | Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof | Chemistry; Metallurgy | 1 | Active |
| US9249220B2 | Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof | Chemistry; Metallurgy | 0 | Active |
| US11407834B2 | Anti-PD-L1 antibody and use thereof | Chemistry; Metallurgy | 0 | Active |
| US11407833B2 | Anti-VISTA antibody and use thereof | Chemistry; Metallurgy | 0 | Active |
| US10155817B2 | Dual-target antibody targeting VEGFR-2 and DLL4 and pharmaceutical composition including same | Physics | 0 | Active |
| US10125194B2 | Dual targeting antibody of novel form, and use thereof | Chemistry; Metallurgy | 0 | Active |
| US9249219B2 | Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof | Chemistry; Metallurgy | 0 | Active |
| US10597457B2 | EGFRvIII antibody and composition comprising same | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.